A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and baseline health measures. Weight loss drugs that target the GLP-1 pathway have moved from a niche diabetes treatment to a mainstream option for obesity care. As their [...]from SciTechDaily https://ift.tt/dmhatCw
